Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

The move is further in line with HHS Secretary Kennedy's anti-vaccine policies ...

Moderna (NASDAQ:MRNA) is escalating its standoff with US regulators at a delicate juncture in its post-pandemic reset. On Friday's analyst call, Chief Executive Officer Stephane Bancel described the ...

In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.

Moby Strategic Execution and Operational Pivot. Achieved a significant financial turning point in 2025 by reducing operating expenses ...

MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.

Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

Applied Materials shares surged after the semiconductor-equipment maker beat analysts’ quarterly earnings estimates.

Dow Jones Top Company Headlines at 5 PM ET: Anthropic Adds New Board Member as It Eyes IPO | Moderna ... The former Microsoft and GM executive Chris Liddell has previously worked for the Trump ...

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient ...